ArticleJournal of thoracic disease2025
Comparison of the efficacy and adverse events between argon-helium cryoablation and microwave ablation for non-small cell lung cancer: a propensity score matching study.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- CT-guided ablation for stage I non-small cell lung cancer: a comparative study between cryoablation and microwave ablation.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Research status and trend of lung cancer ablation therapy: a bibliometric analysis from 2002 to 2025.Journal of thoracic disease · 2026Article
- Integrating cryoablation with immunotherapy in non-small cell lung cancer: mechanisms, clinical evidence, and translational barriers.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Microwave ablation (MWA) and argon-helium cryoablation (AHC) have emerged as widely utilized therapeutic modalities for non-small cell lung cancer (NSCLC) globally, prompting increasing research focus on the comparative clinical characteristics and prognostic outcomes associated with these two ablation techniques. This study aimed to explore the clinical characteristics and prognosis of MWA and AHC in the treatment of NSCLC. Methods: A total of 125 cases of NSCLC treated in the Beijing University of Chinese Medicine Dongzhimen Hospital were retrospectively analysed. To reduce retrospective confounding bias, propensity score matching was performed. We compared the changes in laboratory examination index before and after treatment between the two groups and the occurrence of adverse events after treatment and graded the adverse events. Kaplan-Meier analysis was employed to assess survival rates. Cox regression analysis was employed to ascertain the factors that influence the prognosis of patients. Results: After treatment, the level of systemic inflammatory response in the MWA group exhibited a statistically significant increase (P<0.01), while there was no significant change in the AHC group (P>0.05). The red blood cells and haemoglobin in both groups exhibited a statistically significant decrease (P<0.05). The incidence of bleeding events after treatment in AHC group was higher than that in the MWA group (P<0.05). There was no statistical difference in the grade of adverse events and the overall survival (OS) rate between the two groups (P>0.05). Smoking [hazard ratio (HR), 0.29; 95% confidence interval (CI): 0.09-0.93; P=0.04], chronic obstructive pulmonary disease (COPD) (HR, 0.33; 95% CI: 0.14-0.76; P=0.009) and radiotherapy (HR, 0.11; 95% CI: 0.03-0.34; P=0.001) were independent prognostic factors impacting OS. Conclusions: MWA and AHC are both minimally invasive procedures with proven efficacy in the treatment of NSCLC with a favorable safety profile. However, AHC carries a higher risk of bleeding than MWA. It is recommended that the postoperative management of patients with smoke and COPD should be strengthened to improve their prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.